William Douglas Figg, Sr

William Douglas Figg, Sr

National Institutes of Health - Bethesda, Maryland / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4384450
person_outline William Douglas Figg, Sr's MOST POPULAR ARTICLES
1-) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical … HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ... Journal of clinical oncology: official journal of the American Society of …, 2008 22852008
2-) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ... Journal of Clinical Oncology 17 (11), 3461-3467, 1999 11331999
3-) ThalidomideME Franks, GR Macpherson, WD FiggThe Lancet 363 (9423), 1802-1811, 20048522004
4-) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRL Piekarz, R Frye, M Turner, JJ Wright, SL Allen, MH Kirschbaum, J Zain, ...Journal of clinical oncology 27 (32), 5410-5417, 20098592009
5-) Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinomaAG Duffy, SV Ulahannan, O Makorova-Rusher, O Rahma, H Wedemeyer, ...Journal of hepatology 66 (3), 545-551, 20178082017